Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke
Joseph P Broderick, Olvert A Berkhemer, Yuko Y Palesch, Diederik WJ Dippel, Lydia D Foster, Yvo BWEM Roos, Aad van der Lugt, Thomas A Tomsick, Charles BLM Majoie, Wim H van Zwam, Andrew M Demchuk, Robert J van Oostenbrugge, Pooja Khatri, Hester F Lingsma, Michael D Hill, Bob Roozenbeek, Edward C Jauch, Tudor G Jovin, Bernard Yan, Ruediger von Kummer Show all
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
BACKGROUND AND PURPOSE: We assessed the effect of endovascular treatment in acute ischemic stroke patients with severe neurological deficit (National Institutes of Health Stroke Scale score, ≥20) after a prespecified analysis plan. METHODS: The pooled analysis of the Interventional Management of Stroke III (IMS III) and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trials included participants with an National Institutes of Health Stroke Scale score of ≥20 before intravenous tissue-type plasminogen activator (tPA) treatment (IMS III) or randomization (MR CLEAN) who were treated with intravenous tPA ≤3 hours of stroke ons..View full abstract
Awarded by National Institutes of Health/National Institute of Neurological Disorders and Stroke
Awarded by Alberta Innovates
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
The Interventional Management of Stroke III (IMS III) trial was funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke grant numbers: University of Cincinnati (U01NS052220) and Medical University of South Carolina (U01NS054630 and U01NS077304). Genentech Inc supplied study drug used for intra-arterial tissue-type plasminogen activator treatment in the Endovascular group. EKOS Corp, Concentric Inc, and Cordis Neurovascular Inc supplied study catheters during Protocol Versions 1 to 3. In the United States, IMS III investigator meeting support was provided in part by Genentech Inc, EKOS Corp, and Concentric Inc. In Europe, IMS III investigator meeting support was provided in part by Boehringer Ingelheim. The Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial was funded by the Dutch Heart Foundation and through unrestricted grants from AngioCare BV, Covidien/EV3R, MEDAC Gmbh/LAMEPRO, and Penumbra Inc.